Ipamorelin potential benefits and areas of research

The one benefit ipamorelin has demonstrably delivered is a clean, short-lived pulse of the body's own growth hormone (GH). In rats, swine, and healthy human volunteers it raises GH; in the original characterization it did so without measurably raising ACTH, cortisol, prolactin, LH, FSH, or TSH — the finding that earned it the title "the first selective growth hormone secretagogue" (Raun et al., Eur J Endocrinol 1998). Everything beyond that — muscle, fat loss, recovery, sleep, "anti-aging" — is inference from GH biology. No human trial has tested ipamorelin against any of those endpoints.

The measured effects, with the species they were measured in:

• GH release (rat, swine, human). Potency comparable to GHRP-6 in isolated rat pituitary cells, and a reproducible GH rise in living animals (Raun 1998). In 48 healthy men given 15-minute intravenous infusions, GH peaked around 40 minutes after dosing and fell to very low levels by 6 hours, at every dose tested (Gobburu et al., Pharm Res 1999).

• Bone growth (rat). Fifteen days of dosing raised longitudinal bone growth rate from 42 to 52 µm/day dose-dependently — while leaving total IGF-1, IGF binding proteins, and bone formation and resorption markers unchanged (Johansen et al., Growth Horm IGF Res 1999). Twelve weeks of continuous infusion in adult female rats increased bone mineral content, but through bigger bones rather than denser ones: volumetric bone mineral density did not change (Svensson et al., J Endocrinol 2000).

• Gut motility (rat). Repeated dosing after abdominal surgery increased fecal pellet output, food intake, and body-weight gain in a postoperative ileus model (Venkova et al., J Pharmacol Exp Ther 2009). This is the benefit that got ipamorelin into human trials — and the one the human trial did not reproduce.

Note what is missing from that list: lean mass, fat mass, strength, sleep quality, injury recovery, and skin. No study has measured them.

Ipamorelin's advantage over older growth hormone releasing peptides was never potency — it is roughly as potent as GHRP-6, not more so. The advantage was what it doesn't do. In the 1998 characterization, ipamorelin failed to raise ACTH or cortisol above the level produced by GHRH itself even at doses more than 200 times the GH-releasing dose. That matters because a compound that raises GH while also raising cortisol works against the outcomes people take it for.

Two caveats belong beside that finding. It was established in animals, at single doses; nobody has published a comparable multi-hormone panel across weeks of subcutaneous dosing in humans. And selectivity is a claim about side effects, not about efficacy — a cleaner hormonal profile does not make an unproven benefit more likely.

The marketed benefits rest on a chain of reasoning: ipamorelin raises GH → GH raises IGF-1 → IGF-1 drives muscle growth, repair, and tissue renewal. Each link is real biology. The chain has still never been tested end-to-end for this molecule in people.

The nearest evidence comes from the same receptor family. Two years of oral MK-677 in 65 healthy older adults raised GH and IGF-1 into the young-adult range and added about 1.1 kg of fat-free mass — but produced no improvement in strength or physical function, and raised fasting glucose while insulin sensitivity fell (Nass et al., Ann Intern Med 2008). That is the best-case template for a GH secretagogue: hormone endpoints succeed, functional endpoints do not follow automatically.

When FDA reviewed ipamorelin in 2024, it concluded there were no data supporting effectiveness for either use it had been developed for, by any route of administration (FDA briefing document, 2024).

• GHRP-2 and GHRP-6 — same receptor, less selective; more associated with prolactin and cortisol movement, and (GHRP-6) with hunger.

• CJC-1295 and sermorelin — a different receptor (GHRH), which is why they are paired with ipamorelin in the common blend. No controlled human trial of that combination exists.

• MK-677 — oral, long-acting, and by far the best studied of the group in humans, which is precisely why its limitations are the most visible.

For the counterweight to this page, see ipamorelin side effects and the research and evidence overview.